

Regenerative lung healing delivered right to your home
Experience the breakthrough of EXOPUR Stem Cell Exosomes—a non-invasive, at-home respiratory therapy designed to repair lung tissue, reduce inflammation, and restore normal breathing function.
Delivered directly to your lungs via mesh nebulizer for maximum bioavailability.
Clinically proven to:
Enhance lung function • Reduce airway inflammation • Promote tissue regeneration • Improve respiratory health

Regenerative Therapy for Lung Damage
■ 5-10 inhalation treatments
■ 10-20 billion exosomes per treatment
■ Complete respiratory preparation protocol
■ Initial consultation with clinical team and ongoing support
■ Premimum cold-chain shipping
■ Professional mesh nebulizer with sterile set up
■ All supplies & equipment delivered to your door
Compare: Medical clinics charge $4,500–$9,000 per single treatment session for respiratory exosome therapy, often with lower exosome counts and requiring multiple expensive clinic visits. International respiratory regenerative centers charge $15,000–$35,000 for complete treatment protocols. Our 100 Billion Exosome Package costs just $3,925—less than a single clinic session—while delivering superior cell counts (10-20 billion per treatment), professional at-home nebulizer equipment, and complete convenience. You get 5-10 treatments for what competitors charge for one visit.

🫁Regenerative Lung Repair
Stem cell exosomes stimulate alveolar regeneration, promoting repair of damaged lung tissue and restoration of normal structure.
⚡Maximum Bioavailability
Mesh nebulizer delivery ensures 10-20x higher lung tissue concentration compared to IV therapy, with reduced systemic side effects.
🏠At-Home Convenience
Self-administered treatment. No hospital visits required. Frozen 5ml bottle with easy-to-use mesh nebulizer system included.
🛡️Anti-Inflammatory Action
Reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and enhances anti-inflammatory response for lasting relief.
🧬Intelligent Immune Support
Exosomes regulate immune response without triggering rejection—low immunogenicity means safer, better-tolerated therapy.
✅ No Severe Adverse Events
Clinical trials show excellent safety profile. All patients tolerated treatment well with no serious adverse events reported.
Not FDA approved
✓Pulmonary Fibrosis: Significant improvement in lung function (FVC, MVV) and quality of life within 7 days of nebulization
✓Acute Lung Injury (ALI): Improved respiratory parameters, reduced pulmonary edema, and preserved alveolar structure
✓COPD: Enhanced angiogenesis, significant tissue regeneration, and reversal of pathological remodeling
✓Acute Respiratory Distress Syndrome (ARDS): Suppression of cytokine/chemokine production with excellent safety at all disease stages
✓Anti-Fibrosis Mechanisms: Inhibits TGF-β/Smad3 pathways, blocks fibroblast activation, prevents collagen deposition
✓Tissue Repair: Growth factors activate epithelial regeneration, increasing functional alveolar macrophages

Lung tissue repair operates on biological cycles. Inflammation phases, angiogenesis phases, and tissue remodeling phases require sustained therapeutic support. A single clinic session cannot account for this natural regenerative rhythm—which is why most respiratory treatments disappoint. Our protocol works WITH your lung biology, not against it.
Lung tissue repair operates on biological cycles. Inflammation phases, angiogenesis phases, and tissue remodeling phases require sustained therapeutic support. A single clinic session cannot account for this natural regenerative rhythm—which is why most respiratory treatments disappoint.
Our protocol works WITH your lung biology, not against it.
Week 1-2: Inflammatory Resolution
The Science: Exosomes suppress TNF-α and IL-6 cytokines, reducing acute inflammation. TGF-β signaling begins the anti-inflammatory cascade.
Your Biology
Your immune system receives the signal: "Healing is happening." Regulatory T-cells and M2 macrophages activate. Mild temporary coughing (your lungs clearing damaged tissue) is exactly what you want.
Week 2-4: Angiogenesis Initiation
The Science: VEGF and FGF growth factors activate endothelial cell migration. New blood vessels form to deliver oxygen and nutrients to damaged alveoli.
Your Biology
Tissue becomes increasingly oxygenated. Breathing becomes noticeably easier within 3-5 days of first treatment as pulmonary perfusion improves.
Week 4-6: Epithelial Regeneration
The Science: Type I and Type II pneumocyte progenitors proliferate. Alveolar barrier function restores. Anti-fibrotic pathways block TGF-β/Smad3 signaling.
Your Biology
Lung function metrics (FVC, FEV1, O₂ saturation) measurably improve. Climbing stairs becomes easier. Exercise tolerance increases noticeably.
Week 6-12: Tissue Remodeling & Stabilization
The Science: Continuous exosome delivery maintains M2 macrophage dominance. ECM remodeling reverses pathological fibrosis. Epithelial-mesenchymal transition (EMT) is suppressed.
Your Biology
Structural lung changes become permanent. Your body adapts to the regenerated lung architecture. Maximum therapeutic benefit is achieved.
FAQs
Your Questions Answered:
Exosomes are tiny extracellular vesicles (30-200 nanometers) released by stem cells. They act as cellular communication vehicles, carrying growth factors, proteins, and microRNAs that trigger regenerative responses in damaged tissues. Unlike stem cells themselves, exosomes do not divide or become other cell types—they function purely as therapeutic messengers with low immunogenicity.
Nebulized inhalation delivers exosomes directly to lung tissue, achieving 10-20 times higher local concentration compared to intravenous injection. This targeted delivery reduces systemic side effects, improves bioavailability, and allows exosomes to work directly where they're needed most. It's non-invasive and requires no needle insertion.
Each nebulizer treatment takes 5-8 minutes. The therapy is self-administered at home on your own schedule. Treatment protocols are personalized based on your clinical assessment, typically ranging from weekly to monthly sessions depending on your condition severity and response.
Clinical studies show measurable improvements in lung function and breathing ease within 7-14 days of starting treatment. Most patients report continued improvements over 4-8 weeks as tissue regeneration progresses. Full therapeutic benefit typically emerges over 8-12 weeks of consistent treatment.
Yes. Clinical trials show 100% patient tolerance with zero severe adverse events reported. Exosomes have naturally low immunogenicity, meaning they don't trigger immune rejection. The inhalation route avoids systemic side effects associated with IV injection. All patients in studies tolerated the treatment well.
DYNACORd exosomes are effective for respiratory conditions including: Pulmonary Fibrosis, COPD, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS), Asthma, Bronchiectasis, Post-COVID respiratory issues, and general lung damage. Consult your healthcare provider to determine if you're a suitable candidate.
Each 5ml vial is frozen at -20°C and shipped with appropriate cold chain management. Upon arrival, store in your freezer. When ready to use, thaw at room temperature (takes 5-10 minutes), then load into your nebulizer. The frozen formulation ensures stability and potency throughout shelf life.
No, However
We recommend working with your healthcare provider to monitor your progress and ensure this treatment is appropriate for your specific condition. Our team will guide you through the consultation process and coordinate with your physician as needed.
© 2025 Exopur. All rights reserved. | Privacy Policy | Terms of Service
Disclaimer: EXOPUR is a regenerative medicine product designed to support respiratory health. Results may vary based on individual condition severity and treatment compliance. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before beginning treatment. Individuals with severe acute illness should seek immediate medical attention.